| Schedule of antidilutive shares |
| |
|
September 30, |
|
| |
|
2019 |
|
|
2018 |
|
| Common stock to be issued upon vesting of restricted stock units |
|
|
2,000 |
|
|
|
4,000 |
|
| Common stock to be issued upon exercise of options |
|
|
136,000 |
|
|
|
169,000 |
|
| Common stock to be issued upon exercise of warrants |
|
|
446,000 |
|
|
|
153,000 |
|
| Common stock to be issued upon exercise of common stock units (1) |
|
|
46,000 |
|
|
|
– |
|
| |
|
|
630,000 |
|
|
|
326,000 |
|
|
| Disaggregated Revenue by Source |
| |
|
Three Months Ended September 30,
|
|
|
Six Months Ended September 30,
|
|
| |
|
2019 |
|
|
2018 |
|
|
2019 |
|
|
2018 |
|
| Product |
|
|
|
|
|
|
|
|
|
|
|
|
| Human Skin Care |
|
$ |
3,800,000 |
|
|
$ |
4,074,000 |
|
|
$ |
7,762,000 |
|
|
$ |
7,628,000 |
|
| Animal Skin Care |
|
|
912,000 |
|
|
|
561,000 |
|
|
|
1,335,000 |
|
|
|
1,102,000 |
|
| |
|
|
4,712,000 |
|
|
|
4,635,000 |
|
|
|
9,097,000 |
|
|
|
8,730,000 |
|
| Service |
|
|
256,000 |
|
|
|
304,000 |
|
|
|
582,000 |
|
|
|
578,000 |
|
| Total |
|
$ |
4,968,000 |
|
|
$ |
4,939,000 |
|
|
$ |
9,679,000 |
|
|
$ |
9,308,000 |
|
|